TipRanks
Advertisement
Advertisement

RYTM Stock Latest News

Big Pharma’s Obesity Shopping Spree Is Moving Beyond GLP-1s. Palatin May Fit the Pattern (NASDAQ: PTN)
TipRanks NewswireBig Pharma’s Obesity Shopping Spree Is Moving Beyond GLP-1s. Palatin May Fit the Pattern (NASDAQ: PTN)
16h ago
NVO
PTN
Rhythm Pharmaceuticals initiated with an Outperform at William Blair
PremiumThe Fly
Rhythm Pharmaceuticals initiated with an Outperform at William Blair
6d ago
RYTM
JPMorgan trims Rhythm Pharmaceuticals target, adds to Analyst Focus List
PremiumThe Fly
JPMorgan trims Rhythm Pharmaceuticals target, adds to Analyst Focus List
7d ago
RYTM
Rhythm Pharmaceuticals price target raised to $130 from $105 at H.C. Wainwright
PremiumThe Fly
Rhythm Pharmaceuticals price target raised to $130 from $105 at H.C. Wainwright
10d ago
RYTM
Rhythm Pharmaceuticals price target raised to $150 from $149 at BofA
PremiumThe Fly
Rhythm Pharmaceuticals price target raised to $150 from $149 at BofA
13d ago
RYTM
Analyst Raises Rhythm’s Price Target to $150 and Reaffirms Buy on Strong Imcivree Momentum and Long-Term aHO Penetration Potential
PremiumRatingsAnalyst Raises Rhythm’s Price Target to $150 and Reaffirms Buy on Strong Imcivree Momentum and Long-Term aHO Penetration Potential
13d ago
RYTM
Rhythm Pharmaceuticals price target raised to $159 from $155 at RBC Capital
Premium
The Fly
Rhythm Pharmaceuticals price target raised to $159 from $155 at RBC Capital
14d ago
RYTM
Rhythm announces Health Canada has approved IMCIVREE
Premium
The Fly
Rhythm announces Health Canada has approved IMCIVREE
30d ago
RYTM
Rhythm Pharmaceuticals initiated with an Outperform at Wolfe Research
PremiumThe Fly
Rhythm Pharmaceuticals initiated with an Outperform at Wolfe Research
1M ago
RYTM
GLP-1s Transformed Obesity. Billions Are Now Moving Into Rare Diseases That Require a Different Approach.
PremiumTipRanks Newswire
GLP-1s Transformed Obesity. Billions Are Now Moving Into Rare Diseases That Require a Different Approach.
1M ago
PTN
RYTM
Rhythm Pharmaceuticals assumed with an Outperform at Leerink
PremiumThe Fly
Rhythm Pharmaceuticals assumed with an Outperform at Leerink
1M ago
RYTM
Moderna upgraded, Allstate downgraded: Wall Street’s top analyst calls
PremiumThe Fly
Moderna upgraded, Allstate downgraded: Wall Street’s top analyst calls
2M ago
ALL
EPM
Rhythm Pharmaceuticals initiated with a Hold at Deutsche Bank
PremiumThe FlyRhythm Pharmaceuticals initiated with a Hold at Deutsche Bank
2M ago
RYTM
Rhythm Pharmaceuticals: Buy Rating Reiterated as Japan Approval Extends Imcivree Growth, $150 Price Target Unchanged
Premium
Ratings
Rhythm Pharmaceuticals: Buy Rating Reiterated as Japan Approval Extends Imcivree Growth, $150 Price Target Unchanged
2M ago
RYTM
EMANATE Phase 3 Completion Puts Rhythm’s Genetic Obesity Strategy in Focus
Premium
Company Announcements
EMANATE Phase 3 Completion Puts Rhythm’s Genetic Obesity Strategy in Focus
3M ago
RYTM
Rhythm Pharmaceuticals price target raised to $155 from $141 at RBC Capital
PremiumThe Fly
Rhythm Pharmaceuticals price target raised to $155 from $141 at RBC Capital
3M ago
RYTM
Rhythm Pharmaceuticals price target raised to $154 from $151 at Canaccord
PremiumThe Fly
Rhythm Pharmaceuticals price target raised to $154 from $151 at Canaccord
3M ago
RYTM
Rhythm Pharmaceuticals price target raised to $143 from $142 at Citi
PremiumThe Fly
Rhythm Pharmaceuticals price target raised to $143 from $142 at Citi
3M ago
RYTM
Rhythm Pharmaceuticals price target raised to $160 from $155 at Citizens
PremiumThe Fly
Rhythm Pharmaceuticals price target raised to $160 from $155 at Citizens
3M ago
RYTM
Imcivree’s Strong aHO Momentum and Expanding Market Access Support Buy Rating; $149 Price Target Reiterated
PremiumRatingsImcivree’s Strong aHO Momentum and Expanding Market Access Support Buy Rating; $149 Price Target Reiterated
3M ago
RYTM
Rhythm Pharmaceuticals Earnings Call Signals Momentum
Premium
Company Announcements
Rhythm Pharmaceuticals Earnings Call Signals Momentum
3M ago
RYTM
Rhythm Pharmaceuticals Reports Promising Phase 2 Obesity Data
Premium
Company Announcements
Rhythm Pharmaceuticals Reports Promising Phase 2 Obesity Data
3M ago
8K
RYTM

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >